These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 12969195)
1. Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease. Veljkovic N; Branch DR; Metlas R; Prljic J; Vlahovicek K; Pongor S; Veljkovic V J Pept Res; 2003 Oct; 62(4):158-66. PubMed ID: 12969195 [TBL] [Abstract][Full Text] [Related]
2. Spectral and sequence similarity between vasoactive intestinal peptide and the second conserved region of human immunodeficiency virus type 1 envelope glycoprotein (gp120): possible consequences on prevention and therapy of AIDS. Veljkovic V; Metlas R; Raspopovic J; Pongor S Biochem Biophys Res Commun; 1992 Dec; 189(2):705-10. PubMed ID: 1472041 [TBL] [Abstract][Full Text] [Related]
3. Natural autoantibodies cross-react with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120. Veliković V; Metlas R; Danilo V; Cavor L; Pejinović N; Dujuć A; Zakhariev S; Guarnaccia C; Pongor S Biochem Biophys Res Commun; 1993 Nov; 196(3):1019-24. PubMed ID: 8250861 [TBL] [Abstract][Full Text] [Related]
4. Application of VIP/NTM-reactive natural antibodies in therapy of HIV disease. Veljkovic V; Metlas R Int Rev Immunol; 2004; 23(5-6):437-45. PubMed ID: 15370275 [TBL] [Abstract][Full Text] [Related]
5. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera. Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754 [TBL] [Abstract][Full Text] [Related]
6. Perturbation of in vitro HIV pathogenic effects by peptides showing sequence similarities with the C2 conserved domain of gp120. Lafont V; Nicolas M; Dornand J; Liautard JP; Favero J Immunol Lett; 1993 Aug; 37(2-3):249-50. PubMed ID: 8258463 [No Abstract] [Full Text] [Related]
7. Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer? Veljkovic M; Branch DR; Dopsaj V; Veljkovic V; Veljkovic N; Glisic S; Colombatti A Med Hypotheses; 2011 Sep; 77(3):404-8. PubMed ID: 21684085 [TBL] [Abstract][Full Text] [Related]
8. Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease. Veljkovic N; Branch DR; Metlas R; Prljic J; Manfredi R; Stringer WW; Veljkovic V J Clin Virol; 2004 Dec; 31 Suppl 1():S39-44. PubMed ID: 15567092 [TBL] [Abstract][Full Text] [Related]
9. The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection. Djordjevic A; Veljkovic M; Antoni S; Sakarellos-Daitsiotis M; Krikorian D; Zevgiti S; Dietrich U; Veljkovic N; Branch DR Curr HIV Res; 2007 Sep; 5(5):443-8. PubMed ID: 17896963 [TBL] [Abstract][Full Text] [Related]
10. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630 [TBL] [Abstract][Full Text] [Related]
11. Antigenic activity of three chimeric synthetic peptides of the transmembrane (gp41) and the envelope (gp120) glycoproteins of HIV-1 virus. Marin MH; Peña LP; Tanty CR; Higginson Clarke D; Arenas MA; Noguerol KR; León CS Prep Biochem Biotechnol; 2004 Aug; 34(3):227-37. PubMed ID: 15461139 [TBL] [Abstract][Full Text] [Related]
12. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1. Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494 [TBL] [Abstract][Full Text] [Related]
13. Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition. Vahlne A; Horal P; Eriksson K; Jeansson S; Rymo L; Hedström KG; Czerkinsky C; Holmgren J; Svennerholm B Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10744-8. PubMed ID: 1961741 [TBL] [Abstract][Full Text] [Related]
14. An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions. Ghunaim H; Kumar A; Torres J; Diaz-Mitoma F; Azizi A Vaccine; 2011 Aug; 29(35):5950-8. PubMed ID: 21718739 [TBL] [Abstract][Full Text] [Related]
15. [Evaluation of diagnostic efficiency of the recombinant protein modeling immunodominant epitope V3 of envelope gp120 for immunoenzyme detection for HIV-1 infection antibodies]. Riabinina SA; Baranova EN; Sharipova IN; Susekina MI; Puzyrev VF; Obriadina AP; Burkov AN; Ulanova TI Mol Gen Mikrobiol Virusol; 2007; (3):33-6. PubMed ID: 17886471 [TBL] [Abstract][Full Text] [Related]
16. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993. Sherefa K; Sällberg M; Sönnerborg A AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097 [TBL] [Abstract][Full Text] [Related]
17. Natural autoantibodies in healthy neonatals recognizing a peptide derived from the second conserved region of HIV-1 gp120. Vujicić AD; Gemović B; Veljković V; Glisić S; Veljković N Vojnosanit Pregl; 2014 Apr; 71(4):352-61. PubMed ID: 24783415 [TBL] [Abstract][Full Text] [Related]
18. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847 [TBL] [Abstract][Full Text] [Related]
19. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1). Yu T; Bai Y; Dierich MP; Chen YH Microbiol Immunol; 2000; 44(2):105-10. PubMed ID: 10803497 [TBL] [Abstract][Full Text] [Related]
20. Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. Xiang SH; Farzan M; Si Z; Madani N; Wang L; Rosenberg E; Robinson J; Sodroski J J Virol; 2005 May; 79(10):6068-77. PubMed ID: 15857992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]